Importance of beta cell mass for glycaemic control in people with type 1 diabetes.
Beta cell mass
Exendin
Glucose control
Glucose variability
Hypoglycaemic burden
PET imaging
Pancreatic beta cell
Type 1 diabetes
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
29
06
2022
accepted:
10
10
2022
pubmed:
18
11
2022
medline:
5
1
2023
entrez:
17
11
2022
Statut:
ppublish
Résumé
The role of beta cell mass in the balance of glucose control and hypoglycaemic burden in people with type 1 diabetes is unclear. We applied positron emission tomography (PET) imaging with radiolabelled exendin to compare beta cell mass among people with type 1 diabetes and either low glucose variability (LGV) or high glucose variability (HGV). All participants with either LGV (n=9) or HGV (n=7) underwent a mixed-meal tolerance test to determine beta cell function and wore a blinded continuous glucose monitor for a week. After an i.v. injection with [ Participants with LGV had lower HbA Our data show higher beta cell mass in people with type 1 diabetes and LGV than in those with HGV, independent of beta cell function.
Identifiants
pubmed: 36394644
doi: 10.1007/s00125-022-05830-2
pii: 10.1007/s00125-022-05830-2
pmc: PMC9669532
doi:
Substances chimiques
C-Peptide
0
Blood Glucose
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
367-375Subventions
Organisme : European Commission
ID : 948268
Organisme : Diabetes Fonds
ID : 2015-81-1845
Informations de copyright
© 2022. The Author(s).
Références
American Diabetes Association (2021) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care 44(Suppl 1):S15–S33. https://doi.org/10.2337/dc21-S002
Chatwin H, Broadley M, Speight J et al (2021) The impact of hypoglycaemia on quality of life outcomes among adults with type 1 diabetes: A systematic review. Diabetes Res Clin Pract 174:108752. https://doi.org/10.1016/j.diabres.2021.108752
doi: 10.1016/j.diabres.2021.108752
Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M (2019) The challenge of modulating beta-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol 7(1):52–64. https://doi.org/10.1016/S2213-8587(18)30112-8
doi: 10.1016/S2213-8587(18)30112-8
Oram RA, Jones AG, Besser RE et al (2014) The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 57(1):187–191. https://doi.org/10.1007/s00125-013-3067-x
doi: 10.1007/s00125-013-3067-x
Oram RA, Sims EK, Evans-Molina C (2019) Beta cells in type 1 diabetes: mass and function; sleeping or dead? Diabetologia 62(4):567–577. https://doi.org/10.1007/s00125-019-4822-4
doi: 10.1007/s00125-019-4822-4
Yu MG, Keenan HA, Shah HS et al (2019) Residual beta cell function and monogenic variants in long-duration type 1 diabetes patients. J Clin Invest 129(8):3252–3263. https://doi.org/10.1172/JCI127397
doi: 10.1172/JCI127397
Keenan HA, Sun JK, Levine J et al (2010) Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 59(11):2846–2853. https://doi.org/10.2337/db10-0676
doi: 10.2337/db10-0676
Oram RA, McDonald TJ, Shields BM et al (2015) Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. Diabetes Care 38(2):323–328. https://doi.org/10.2337/dc14-0871
doi: 10.2337/dc14-0871
Sims EK, Bahnson HT, Nyalwidhe J et al (2018) Proinsulin secretion is a persistent feature of type 1 diabetes. Diabetes Care. https://doi.org/10.2337/dc17-2625
Rodriguez-Calvo T, Zapardiel-Gonzalo J, Amirian N et al (2017) Increase in pancreatic proinsulin and preservation of beta-cell mass in autoantibody-positive donors prior to type 1 diabetes onset. Diabetes 66(5):1334–1345. https://doi.org/10.2337/db16-1343
doi: 10.2337/db16-1343
Sims EK, Syed F, Nyalwidhe J et al (2019) Abnormalities in proinsulin processing in islets from individuals with longstanding T1D. Transl Res. https://doi.org/10.1016/j.trsl.2019.08.001
Gibb FW, McKnight JA, Clarke C, Strachan MWJ (2020) Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes. Diabetologia 63(5):906–914. https://doi.org/10.1007/s00125-020-05099-3
doi: 10.1007/s00125-020-05099-3
Fukuda M, Tanaka A, Tahara Y et al (1988) Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes 37(1):81–88. https://doi.org/10.2337/diabetes.37.1.81
doi: 10.2337/diabetes.37.1.81
Boss M, Buitinga M, Jansen TJ, Brom M, Visser EP, Gotthardt M (2019) PET-based dosimetry of [(68)Ga]Ga-NODAGA-exendin-4 in humans, a tracer for beta cell imaging. J Nucl Med Off Publ Soc Nucl Med. https://doi.org/10.2967/jnumed.119.228627
Brom M, Joosten L, Frielink C, Boerman O, Gotthardt M (2015) (111)In-exendin uptake in the pancreas correlates with the beta-cell mass and not with the alpha-cell mass. Diabetes 64(4):1324–1328. https://doi.org/10.2337/db14-1212
doi: 10.2337/db14-1212
Brom M, Joosten L, Frielink C et al (2018) Validation of (111)In-exendin SPECT for the determination of the beta-cell mass in biobreeding diabetes-prone rats. Diabetes 67(10):2012–2018. https://doi.org/10.2337/db17-1312
doi: 10.2337/db17-1312
Brom M, Woliner-van der Weg W, Joosten L et al (2014) Non-invasive quantification of the beta cell mass by SPECT with (1)(1)(1)In-labelled exendin. Diabetologia 57(5):950–959. https://doi.org/10.1007/s00125-014-3166-3
doi: 10.1007/s00125-014-3166-3
Joosten L, Brom M, Peeters H et al (2019) Measuring the pancreatic beta cell mass in vivo with exendin SPECT during hyperglycemia and severe insulitis. Mol Pharm 16(9):4024–4030. https://doi.org/10.1021/acs.molpharmaceut.9b00728
doi: 10.1021/acs.molpharmaceut.9b00728
Gotthardt M, Eizirik DL, Aanstoot HJ et al (2018) Detection and quantification of beta cells by PET imaging: why clinical implementation has never been closer. Diabetologia. https://doi.org/10.1007/s00125-018-4745-5
Janssen MM, Snoek FJ, Heine RJ (2000) Assessing impaired hypoglycemia awareness in type 1 diabetes: agreement of self-report but not of field study data with the autonomic symptom threshold during experimental hypoglycemia. Diabetes Care 23(4):529–532. https://doi.org/10.2337/diacare.23.4.529
doi: 10.2337/diacare.23.4.529
International Hypoglycaemia Study Group (2017) Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 60(1):3–6. https://doi.org/10.1007/s00125-016-4146-6 . Erratum: 60:377. https://doi.org/10.1007/s00125-016-4168-0
Moran A, Bundy B, Becker DJ et al (2013) Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381(9881):1905–1915. https://doi.org/10.1016/s0140-6736(13)60023-9
doi: 10.1016/s0140-6736(13)60023-9
Lam CJ, Jacobson DR, Rankin MM, Cox AR, Kushner JA (2017) beta cells persist in T1D pancreata without evidence of ongoing beta-cell turnover or neogenesis. J Clin Endocrinol Metab 102(8):2647–2659. https://doi.org/10.1210/jc.2016-3806
doi: 10.1210/jc.2016-3806
Rodriguez-Calvo T, Richardson SJ, Pugliese A (2018) Pancreas pathology during the natural history of type 1 diabetes. Curr Diab Rep 18(11):124. https://doi.org/10.1007/s11892-018-1084-3
doi: 10.1007/s11892-018-1084-3
Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC (2005) Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 48(11):2221–2228. https://doi.org/10.1007/s00125-005-1949-2
doi: 10.1007/s00125-005-1949-2
Lachin JM, McGee P, Palmer JP, Group DER (2014) Impact of C-peptide preservation on metabolic and clinical outcomes in the diabetes control and complications trial. Diabetes 63(2):739–748. https://doi.org/10.2337/db13-0881
doi: 10.2337/db13-0881
Rickels MR, Evans-Molina C, Bahnson HT et al (2020) High residual C-peptide likely contributes to glycemic control in type 1 diabetes. J Clin Invest 130(4):1850–1862. https://doi.org/10.1172/JCI134057
doi: 10.1172/JCI134057
Banarer S, McGregor VP, Cryer PE (2002) Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 51(4):958–965. https://doi.org/10.2337/diabetes.51.4.958
doi: 10.2337/diabetes.51.4.958
Segerstolpe A, Palasantza A, Eliasson P et al (2016) Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes. Cell Metab 24(4):593–607. https://doi.org/10.1016/j.cmet.2016.08.020
doi: 10.1016/j.cmet.2016.08.020
Wright JJ, Saunders DC, Dai C et al (2020) Decreased pancreatic acinar cell number in type 1 diabetes. Diabetologia 63(7):1418–1423. https://doi.org/10.1007/s00125-020-05155-y
doi: 10.1007/s00125-020-05155-y
Arrojo EDR, Jacob S, Garcia-Prieto CF et al (2019) Structural basis for delta cell paracrine regulation in pancreatic islets. Nat Commun 10(1):3700. https://doi.org/10.1038/s41467-019-11517-x
doi: 10.1038/s41467-019-11517-x
Xu G, Kaneto H, Laybutt DR et al (2007) Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56(6):1551–1558. https://doi.org/10.2337/db06-1033
doi: 10.2337/db06-1033
Rajan S, Dickson LM, Mathew E et al (2015) Chronic hyperglycemia downregulates GLP-1 receptor signaling in pancreatic beta-cells via protein kinase A. Mol Metab 4(4):265–276. https://doi.org/10.1016/j.molmet.2015.01.010
doi: 10.1016/j.molmet.2015.01.010
Buitinga M, Cohrs CM, Eter WA et al (2020) Noninvasive monitoring of glycemia-induced regulation of GLP-1R expression in murine and human islets of langerhans. Diabetes 69(11):2246–2252. https://doi.org/10.2337/db20-0616
doi: 10.2337/db20-0616
Campbell SA, Golec DP, Hubert M et al (2020) Human islets contain a subpopulation of glucagon-like peptide-1 secreting alpha cells that is increased in type 2 diabetes. Mol Metab 39:101014. https://doi.org/10.1016/j.molmet.2020.101014
doi: 10.1016/j.molmet.2020.101014
de Souza AH, Tang J, Yadev AK et al (2020) Intra-islet GLP-1, but not CCK, is necessary for beta-cell function in mouse and human islets. Sci Rep 10(1):2823. https://doi.org/10.1038/s41598-020-59799-2
doi: 10.1038/s41598-020-59799-2
Virostko J, Williams J, Hilmes M et al (2019) Pancreas volume declines during the first year after diagnosis of type 1 diabetes and exhibits altered diffusion at disease onset. Diabetes Care 42(2):248–257. https://doi.org/10.2337/dc18-1507
doi: 10.2337/dc18-1507
Velikyan I, Haack T, Bossart M et al (2019) First-in-class positron emission tomography tracer for the glucagon receptor. EJNMMI Res 9(1):17. https://doi.org/10.1186/s13550-019-0482-0
doi: 10.1186/s13550-019-0482-0
Eriksson O, Velikyan I, Haack T et al (2021) Imaging of the glucagon receptor in subjects with type 2 diabetes. J Nucl Med Off Publ Soc Nucl Med 62(6):833–838. https://doi.org/10.2967/jnumed.118.213306
doi: 10.2967/jnumed.118.213306
Krogvold L, Edwin B, Buanes T et al (2014) Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia 57(4):841–843. https://doi.org/10.1007/s00125-013-3155-y
doi: 10.1007/s00125-013-3155-y
Shah VN, Wu M, Polsky S et al (2018) Gender differences in diabetes self-care in adults with type 1 diabetes: Findings from the T1D exchange clinic registry. J Diabetes Complicat 32(10):961–965. https://doi.org/10.1016/j.jdiacomp.2018.08.009
doi: 10.1016/j.jdiacomp.2018.08.009